A case report on generalized pemphigus vulgaris treated with rituximaba

Background: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with autoimmune disease. Rituximab a monoclonal antibody that specifically targets CD20 antigen B lymphocytes, arisen as novel treatment approach for pemphigus vulgaris. Case presentation: A 39-year-old male patient presented three-month history mouth ulcers, poor oral hygiene accompanied heavy tobacco smoking and alcohol consumption. He was diagnosed The disease gradually progressed to involve other body parts. had shown partial improvement after conventional therapy (oral cefuroxime, prednisolone azathioprine) later on successfully treated rituximab. After 90 days follow-up, no future recurrence observed. Conclusion: With this case, authors would like aware clinicians potential use rituximab in treating vulgaris, especially when fails.